EB7_DETAILS

Rx Plans May Exclude Value of Drug Manufacturers’ Coupons Until Further Notice

09/04/2019 Written by: Patrick Haynes

The DOL, HHS, and IRS have jointly issued an FAQ addressing whether health plans must count drug manufacturers’ coupons toward the annual cost-sharing limits under the Affordable Care Act (ACA). (Note: these limits apply to non-grandfathered group health plans, including self-insured and insured small and large group market health plans.) Regulations that announced the 2020 benefit and payment parameters (including the maximum annual cost-sharing limits) provided that, for plan years beginning on or after January 1, 2020, plans and insurers need not count the value of drug manufacturers’ coupons toward the annual cost-sharing limits when a medically appropriate generic equivalent is available. Please see our May 9, 2019 post about the 2020 limits here.
After the regulations were released, stakeholders pointed out that this provision implies that, in any other circumstances, plans and insurers must count such coupon amounts toward the annual cost-sharing limits, and that such a requirement could create a conflict with certain rules for high deductible health plans (HDHPs) that are intended to allow eligible individuals to establish HSAs.
Explaining that, for purposes of determining whether the HDHP minimum deductible has been satisfied, HDHPs must disregard drug discounts and other manufacturers’ and providers’ discounts and may only take into account amounts actually paid by the individual, the FAQ acknowledges that HDHP insurers or sponsors may be unable to comply with both rules simultaneously. The agencies intend to address this conflict in the regulations that announce the 2021 benefit and payment parameters. Until such regulations are effective, the agencies will not initiate an enforcement action if an insurer or plan excludes the value of drug manufacturers’ coupons from the annual cost-sharing limits, including when no medically appropriate generic equivalent is available.
The rule announced in the 2020 benefit and payment parameters was intended to discourage providers and patients from choosing expensive brand-name drugs when a less expensive and equally effective alternative is available. HHS also proposed other rules designed to encourage the use of generic drugs but did not include them in the final parameters, noting their complexity and administrative burden. It will be interesting to see what direction the agencies take when the 2021 benefit and payment parameters are proposed, including how they reconcile any conflicting rules such as the one addressed in this FAQ.
Links:


Supporting-Women-at-Work
Supporting Women at Work
Employee Benefits06/20/2024

In the last decade, women have made their voices heard about how their roles differ from their male counterparts in the workplace; however, the topic of conversation has moved past the pay equality...

The-Importance-of-Family-Friendly-Benefits-in-the-Workplace
The Importance of Family-Friendly Benefits in the Workplace
Employee Benefits06/18/2024

Family-friendly benefits in the workplace are becoming more and more important to workers today, and when designed properly, can help businesses attract and retain top talent, improve employee...

Protecting-Your-Travel 
Protecting Your Travel
Employee Benefits06/17/2024

There is much thought that goes into planning an exciting trip, but when it comes to travel, careful planning only takes you so far. Travel insurance can help fill the gaps, helping you recover costs...